Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic

  • Read more about Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic

Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022

  • Read more about Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022

Bone Therapeutics: Information on the total number of voting rights and shares

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares

Bone Therapeutics to host Extraordinary General Meeting on 05 October 2022

  • Read more about Bone Therapeutics to host Extraordinary General Meeting on 05 October 2022

Bone Therapeutics reports half year 2022 results

  • Read more about Bone Therapeutics reports half year 2022 results

Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

  • Read more about Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

Bone Therapeutics: Information on the total number of voting rights and shares (May 2020)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (May 2020)

Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study

  • Read more about Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study

Bone Therapeutics to host Annual Ordinary General Meeting on 10 June 2020

  • Read more about Bone Therapeutics to host Annual Ordinary General Meeting on 10 June 2020

Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15 million committed, providing runway into Q2 2021

  • Read more about Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15 million committed, providing runway into Q2 2021

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions